Phase IIa Study for IPG11406 in Patients With Lupus Nephritis

Recruiting now · Phase 1/Phase 2

Conditions studied: Lupus Nephritis

In brief

A multi-center, multi-dose phase Ib/IIa clinical study evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics, and impact on biomarkers of IPG11406 in patients with Lupus Nephritis

Key facts

Study ID
NCT06717815
Run by
Nanjing Immunophage Biotech Co., Ltd
People needed
36
Starts
2025-02-25
Expected to finish
2026-04-22
Last updated by the study team
2026-01-13

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.